ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented the Omnipod DASH® Insulin Management System (Omnipod DASH) to healthcare providers attending the virtual Australasian Diabetes Congress. Insulet expects to begin taking customer orders for Omnipod DASH by the end of August.
“As part of our ongoing efforts to bring Omnipod technology to more people living with diabetes around the world, we’re excited to announce that Omnipod DASH will soon be available in Australia,” said Bret Christensen, Chief Commercial Officer of Insulet. “As the first waterproof, wearable tubeless pump available in this country, Omnipod DASH will offer insulin-requiring Australians the freedom, flexibility, and discretion needed to simplify their diabetes management.”
Insulet’s planned launch in Australia is part of its global expansion strategy, which included five additional European and Middle Eastern markets in 2020, as well as Turkey earlier this year.
Omnipod DASH includes two parts: a sleek, touchscreen Personal Diabetes Manager (PDM) with an intuitive interface, and a waterproof1, wearable Pod that provides up to 72 hours2 of continuous insulin therapy. The system allows customers to deliver insulin through customizable basal and bolus amounts with no daily injections and no tubes.
Professor David O’Neal from St Vincent’s Hospital in Melbourne, Victoria is amongst the first healthcare professionals to prescribe Omnipod DASH to patients. “I am very pleased that people in Australia who are considering an insulin pump will soon have Omnipod DASH as an option,” he said. “With the benefit of a bolus calculator and without the intrusiveness associated with conventional tubed insulin pumps, Pod therapy is easy to use, extremely intuitive, and will provide flexibility in insulin delivery.”
Along with Omnipod’s innovative form factor, Insulet also offers a customer-centric business model that better fits the changing needs of people with diabetes. Omnipod users have no high upfront costs or four-year lock-in period, which keeps payment terms simple, making this a flexible choice for the diabetes community. It allows more people with diabetes to try the benefits of insulin pump therapy.
“I am beyond excited that Omnipod DASH is coming to Australia. It has been life changing and perfectly complements my active lifestyle. The feeling of no tubes and waterproof, combined with the flexibility of an insulin pump as opposed to injections, is completely liberating,” said Will Goyder, an active Australian living with type 1 diabetes who has benefitted from early access to Omnipod.
For more information, visit please visit omnipod.com.
1. The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM is not waterproof.
2. Up to 72 hours of continuous insulin delivery.
About the Omnipod DASH® System:
The Omnipod DASH Insulin Management System is the first and only waterproof, tubeless device that can provide three days of non-stop insulin delivery. Its unique design consists of just two parts; a lightweight, tubeless, waterproof, wearable Pod controlled by a smartphone touch-screen Bluetooth® enabled controller, minimizing the number of components to carry. The Omnipod DASH System offers simple, smart, discreet insulin control for people diagnosed with type 1 or insulin-requiring type 2 diabetes. The Omnipod DASH System, which received FDA clearance in June 2018 and TGA approval in September 2020, is the only DTSec and ISO 27001 certified insulin pump for cyber and information security and safety.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 24, 2021 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
©2021 Insulet Corporation. Omnipod DASH is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.